NervGen Pharma Corp. Common stock (NGEN) EBITDA Yield: History & Chart

NervGen Pharma Corp. Common stock(NGEN)

Biotechnology · West Vancouver, BC

$1.82+0.00 (+0.28%)

Delayed quote: Oct 6, 2026, 12:55 PM EDT

About NervGen Pharma Corp. Common stock

NervGen Pharma Corp., a biotechnology company, engages in the discovery, development, and commercialization of pharmaceutical treatments to promote nervous system repair in settings of neurotrauma and neurologic disease. The company's lead product candidate is NVG-291 that is in Phase 1b/2a clinical trial for the treatment of spinal cord injuries (SCI), stroke, multiple sclerosis, and Alzheimer's disease; and NVG-300, which is in a preclinical model of ischemic stroke, amyotrophic lateral sclerosis, and confirmatory SCI study. NervGen Pharma Corp. has a licensing agreement with Case Western Reserve University to develop and commercialize a patented technology with therapeutic potential for spinal cord injury and other conditions associated with nerve damage. NervGen Pharma Corp. was incorporated in 2017 and is headquartered in Vancouver, Canada.

West Vancouver, BC

8 employees

www.nervgen.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Adam H. Rogers

View full financials

NAME	MARKET CAP	EBITDA YIELD	TTM	3Y	5Y
NervGen Pharma Corp. Common stock (NGEN)	$149.18M	N/A	N/A	N/A	N/A
LifeMD, Inc. (LFMDP)vs ›	$148.31M	N/A	0.81%	0.81%	0.81%
Acumen Pharmaceuticals, Inc. (ABOS)vs ›	$146.98M	N/A	N/A	N/A	N/A
Anavex Life Sciences Corp. (AVXL)vs ›	$146.88M	N/A	N/A	N/A	N/A
Cardiol Therapeutics Inc. (CRDL)vs ›	$151.58M	N/A	N/A	N/A	N/A
Codexis, Inc. (CDXS)vs ›	$151.65M	N/A	1.29%	1.28%	1.28%
ALX Oncology Holdings Inc. (ALXO)vs ›	$152.73M	N/A	N/A	N/A	N/A
Korsana Biosciences, Inc. (KRSA)vs ›	$144.84M	N/A	N/A	N/A	N/A
Nyxoah S.A. (NYXH)vs ›	$144.10M	N/A	N/A	N/A	N/A
Immuneering Corporation (IMRX)vs ›	$142.31M	N/A	N/A	N/A	N/A

NAME

MARKET CAP

EBITDA YIELD

TTM

NervGen Pharma Corp. Common stock (NGEN)

$149.18M

N/A

LifeMD, Inc. (LFMDP)vs ›

$148.31M

N/A

0.81%

Acumen Pharmaceuticals, Inc. (ABOS)vs ›

$146.98M

N/A

Anavex Life Sciences Corp. (AVXL)vs ›

$146.88M

N/A

Cardiol Therapeutics Inc. (CRDL)vs ›

$151.58M

N/A

Codexis, Inc. (CDXS)vs ›

$151.65M

N/A

1.29%

1.28%

ALX Oncology Holdings Inc. (ALXO)vs ›

$152.73M

N/A

Korsana Biosciences, Inc. (KRSA)vs ›

$144.84M

N/A

Nyxoah S.A. (NYXH)vs ›

$144.10M

N/A

Immuneering Corporation (IMRX)vs ›

$142.31M

N/A

EBITDA Yield Formula & Definition

EBITDA Yield = TTM EBITDA / Enterprise Value

EBITDA yield is the inverse of EV/EBITDA, expressing trailing pre-interest, pre-tax operating cash generation as a percentage of enterprise value. Comparable across leverage levels; higher is cheaper. Not meaningful for banks and insurers.

EBITDA Yield: N/A

NGEN EBITDA Yield Metrics

NGEN Competitors' EBITDA Yield

EBITDA Yield Formula & Definition

Related Metrics